Lixte Biotechnology Holdings, Inc.
LIXT
$4.86
-$0.01-0.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.32M | -3.59M | -4.00M | -4.03M | -4.69M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 415.20K | 418.40K | 444.50K | 449.80K | 599.20K |
| Change in Net Operating Assets | -34.90K | 3.00K | 88.10K | 128.80K | 280.50K |
| Cash from Operations | -2.94M | -3.16M | -3.47M | -3.45M | -3.81M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 914.20K | -- | 362.90K | 3.50M | 3.50M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -362.90K | -362.90K | -362.90K |
| Cash from Financing | 914.20K | -- | 0.00 | 3.14M | 3.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.03M | -3.16M | -3.47M | -317.60K | -674.00K |